Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Mayne Pharma Group ( (AU:MYX) ).
Mayne Pharma has convened its 2025 Annual General Meeting in Melbourne on 29 January 2026, following an extension granted by the corporate regulator due to delays in completing its proposed Scheme of Arrangement with Cosette Pharmaceuticals. The Chair, Professor Bruce Robinson, formally opened the hybrid AGM, outlined participation and voting procedures for both in-person and online shareholders, and introduced the board, senior executives and auditor, underscoring the company’s ongoing governance processes despite the setback in finalising the Cosette transaction.
The most recent analyst rating on (AU:MYX) stock is a Sell with a A$2.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company, focused on developing and manufacturing branded and generic medicines for global markets, with shares listed on the ASX and a significant presence in both Australia and the United States.
Average Trading Volume: 564,661
Technical Sentiment Signal: Sell
Current Market Cap: A$235.6M
Find detailed analytics on MYX stock on TipRanks’ Stock Analysis page.